Ashton Thomas Private Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ashton Thomas Private Wealth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455K	Sell	3,560 -600	-14%	-$74.9K	0.01%	750
2025 Q4	$507K	Hold	4,160	–	–	0.01%	660
2025 Q3	$417K	Buy	+4,160	New	+$375K	0.01%	682
2024 Q3	–	Sell	-1,494	Closed	-$139K	–	1868
2024 Q2	$139K	Buy	+1,494	New	+$134K	0.01%	673
2022 Q2	–	Sell	-2,743	Closed	-$247K	–	494
2022 Q1	$247K	Sell	2,743 -52	-2%	-$4.8K	0.02%	434
2021 Q4	$313K	Buy	2,795 +851	+44%	+$103K	0.03%	383
2021 Q3	$244K	Buy	+1,944	New	+$250K	0.04%	330

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ashton Thomas Private Wealth's XBI Position: Q1 2026 in Review

Ashton Thomas Private Wealth reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 14% in Q1 2026, selling an estimated $74.9K and leaving 3,560 shares worth $455K. The position accounts for 0.01% of the portfolio, ranked #750.

Ashton Thomas Private Wealth first reported a position in XBI in Q3 2021 and has held it in 7 quarters since. The position peaked at $507K in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Ashton Thomas Private Wealth held 3,560 shares of State Street SPDR S&P Biotech ETF worth $455K as of Q1 2026.
Ashton Thomas Private Wealth sold 600 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $74.9K.
State Street SPDR S&P Biotech ETF made up 0.01% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #750 holding.
Ashton Thomas Private Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and has held it in 7 quarters since.
Ashton Thomas Private Wealth's State Street SPDR S&P Biotech ETF position peaked at $507K in Q4 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.